(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 2.36% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.43%.
Illumina's revenue in 2025 is $4,372,000,000.On average, 6 Wall Street analysts forecast ILMN's revenue for 2025 to be $682,889,169,600, with the lowest ILMN revenue forecast at $651,816,000,000, and the highest ILMN revenue forecast at $702,722,592,000. On average, 6 Wall Street analysts forecast ILMN's revenue for 2026 to be $720,901,051,200, with the lowest ILMN revenue forecast at $696,009,600,000, and the highest ILMN revenue forecast at $741,717,504,000.
In 2027, ILMN is forecast to generate $775,534,636,800 in revenue, with the lowest revenue forecast at $744,004,800,000 and the highest revenue forecast at $799,915,248,000.